Rothschild Asset Management Inc. lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,127,218 shares of the specialty pharmaceutical company’s stock after selling 45,647 shares during the quarter. Rothschild Asset Management Inc. owned about 2.22% of Supernus Pharmaceuticals worth $45,089,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of SUPN. Vanguard Group Inc. raised its stake in Supernus Pharmaceuticals by 39.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after purchasing an additional 984,200 shares during the period. Emerald Advisers Inc. PA purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $21,474,000. Emerald Mutual Fund Advisers Trust purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $17,553,000. Pictet Asset Management Ltd. grew its holdings in Supernus Pharmaceuticals by 438.7% during the 3rd quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock valued at $19,651,000 after buying an additional 400,083 shares in the last quarter. Finally, Hodges Capital Management Inc. purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $17,220,000. 94.70% of the stock is currently owned by institutional investors.

Several equities analysts have weighed in on the company. Stifel Nicolaus cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price target for the company. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Cantor Fitzgerald restated a “buy” rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a report on Tuesday, September 19th. Piper Jaffray Companies restated a “hold” rating and set a $45.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, September 8th. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $61.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $49.60.

In related news, insider Stefan K.F. Schwabe sold 95,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Gregory S. Patrick sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $47.60, for a total value of $2,380,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 150,000 shares of company stock valued at $7,055,350. Company insiders own 6.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/20/supernus-pharmaceuticals-inc-supn-position-cut-by-rothschild-asset-management-inc.html.

Shares of Supernus Pharmaceuticals, Inc. (SUPN) traded up $0.10 during trading on Monday, hitting $38.00. The stock had a trading volume of 459,600 shares, compared to its average volume of 619,784. The stock has a market cap of $1,950.00, a PE ratio of 35.85, a price-to-earnings-growth ratio of 1.61 and a beta of 1.30. Supernus Pharmaceuticals, Inc. has a 12-month low of $20.55 and a 12-month high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business’s revenue for the quarter was up 41.5% on a year-over-year basis. equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.07 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.